MTG201

Developed for: malignant pleural mesothelioma
Investigated by: Baylor College of Medicine · Momotaro-Gene Inc. · Synteract, Inc.

today NCT04013334 · Ph 2

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT04013334	Aug 2019 → Dec 2022	malignant pleural mesothelioma	Momotaro-Gene Inc.	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	MTG201	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04013334 ↗
Route	Other	“delivered by intratumoral injection” NCT04013334 ↗